For example, the recent evidence that BCG induced IFNγ can protect mice from SCV2 challenge (34, 41) raises the question of whether the cytokine could be used intranasally to protect subjects at high risk of infection possibly with less risk of toxicity than Type I IFN. This evidence concerns the gene IFNG and infection.